Biological effects in normal cells exposed to FLASH dose rate protons.
Proton FLASH dose rate
Proton FLASH irradiation
Proton FLASH therapy
Proton dose rate effects
Proton radiotherapy
Journal
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
21
11
2018
revised:
04
02
2019
accepted:
11
02
2019
pubmed:
10
3
2019
medline:
21
4
2020
entrez:
10
3
2019
Statut:
ppublish
Résumé
Radiotherapy outcomes are limited by toxicity in the healthy tissues surrounding the irradiated tumor. Recent pre-clinical studies have shown that irradiations with electrons or photons delivered at so called FLASH dose rates (i.e. >40 Gy/s) dramatically reduce adverse side effects in the normal tissues while being equally efficient for tumor control as irradiations at conventional dose rates (3-5 cGy/s). In the case of protons however, FLASH effects have not been investigated partially because of the limited availability of facilities that can achieve such high dose rates. Using a novel irradiation platform, we measured acute and long-term biological effects in normal human lung fibroblasts (IMR90) exposed to therapeutically relevant doses of 4.5 MeV protons (LET = 10 keV/µm) delivered at dose rates spanning four orders of magnitude. Endpoints included clonogenic cell survival, γH2AX foci formation, induction of premature senescence (β-gal), and the expression of the pro-inflammatory marker TGFβ. Proton dose rate had no influence on the cell survival, but for the highest dose rate used (i.e. 1000 Gy/s) foci formation saturated beyond 10 Gy. In the progeny of irradiated cells, an increase in dose (20 Gy vs. 10 Gy) and dose rate (1000 Gy/s vs. 0.05 Gy/s) positively affected the number of senescence cells and the expression of TGFβ1. In normal lung fibroblasts proton dose rate had little impact on acute effects, but significantly influenced the expression of long-term biological responses in vitro. Compared to conventional dose rates, protons delivered at FLASH dose rates mitigated such delayed detrimental effects.
Sections du résumé
BACKGROUND
Radiotherapy outcomes are limited by toxicity in the healthy tissues surrounding the irradiated tumor. Recent pre-clinical studies have shown that irradiations with electrons or photons delivered at so called FLASH dose rates (i.e. >40 Gy/s) dramatically reduce adverse side effects in the normal tissues while being equally efficient for tumor control as irradiations at conventional dose rates (3-5 cGy/s). In the case of protons however, FLASH effects have not been investigated partially because of the limited availability of facilities that can achieve such high dose rates.
METHODS
Using a novel irradiation platform, we measured acute and long-term biological effects in normal human lung fibroblasts (IMR90) exposed to therapeutically relevant doses of 4.5 MeV protons (LET = 10 keV/µm) delivered at dose rates spanning four orders of magnitude. Endpoints included clonogenic cell survival, γH2AX foci formation, induction of premature senescence (β-gal), and the expression of the pro-inflammatory marker TGFβ.
RESULTS
Proton dose rate had no influence on the cell survival, but for the highest dose rate used (i.e. 1000 Gy/s) foci formation saturated beyond 10 Gy. In the progeny of irradiated cells, an increase in dose (20 Gy vs. 10 Gy) and dose rate (1000 Gy/s vs. 0.05 Gy/s) positively affected the number of senescence cells and the expression of TGFβ1.
CONCLUSIONS
In normal lung fibroblasts proton dose rate had little impact on acute effects, but significantly influenced the expression of long-term biological responses in vitro. Compared to conventional dose rates, protons delivered at FLASH dose rates mitigated such delayed detrimental effects.
Identifiants
pubmed: 30850209
pii: S0167-8140(19)30076-3
doi: 10.1016/j.radonc.2019.02.009
pmc: PMC6728238
mid: NIHMS1523306
pii:
doi:
Substances chimiques
Protons
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
51-55Subventions
Organisme : NIBIB NIH HHS
ID : P41 EB002033
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.
Références
Radiat Environ Biophys. 2012 Mar;51(1):23-32
pubmed: 22228542
Radiat Res. 2014 Feb;181(2):177-83
pubmed: 24524347
Radiat Res. 1979 May;78(2):192-209
pubmed: 451151
J Clin Oncol. 2018 Jun 20;36(18):1823-1830
pubmed: 29561693
Radiother Oncol. 2018 Dec;129(3):582-588
pubmed: 30177374
Phys Med Biol. 2014 Nov 21;59(22):R419-72
pubmed: 25361443
J Exp Med. 1956 May 1;103(5):653-66
pubmed: 13319584
Stat Med. 1995 Apr 30;14(8):811-9
pubmed: 7644861
Radiat Res. 2011 Jun;175(6):719-27
pubmed: 21438661
Med Phys. 2010 Oct;37(10):5376-81
pubmed: 21089773
Radiat Res. 1980 May;82(2):277-89
pubmed: 6246560
Clin Cancer Res. 2019 Jan 1;25(1):35-42
pubmed: 29875213
Mutat Res. 2011 Jun 3;711(1-2):193-201
pubmed: 21216256
Acta Oncol. 2017 Nov;56(11):1359-1366
pubmed: 28828925
Phys Med Biol. 2018 Dec 18;63(24):245021
pubmed: 30524014
Sci Transl Med. 2014 Jul 16;6(245):245ra93
pubmed: 25031268
Cancer Lett. 2012 Dec 31;327(1-2):48-60
pubmed: 22182453
Radiat Res. 2011 Apr;175(4):405-15
pubmed: 21319986
J Natl Cancer Inst. 2013 Oct 2;105(19):1474-84
pubmed: 24052614
Radiat Oncol. 2011 Oct 18;6:139
pubmed: 22008289
Radiat Res. 2011 Mar;175(3):282-90
pubmed: 21388271
Radiother Oncol. 2010 Apr;95(1):66-72
pubmed: 20347168
Cancers (Basel). 2015 Jun 29;7(3):1143-53
pubmed: 26132317
Int J Radiat Biol. 2010 Aug;86(8):682-91
pubmed: 20569192
N Engl J Med. 2017 Nov 30;377(22):2200-2201
pubmed: 29171815
Radiother Oncol. 2012 Apr;103(1):8-11
pubmed: 22405807